ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2020 and some content may be unavailable. To unlock all content for 2020, please visit the archives.

Abstract: PO1012

Renal Outcomes and All-Cause Death Associated with SGLT-2 Inhibitor vs. Other Glucose-Lowering Drugs (CVD-REAL 3 Korea)

Session Information

Category: Diabetic Kidney Disease

  • 602 Diabetic Kidney Disease: Clinical

Authors

  • Koh, Eun Sil, The Catholic University of Korea Yeouido Saint Mary's Hospital, Yeongdeungpo-gu, Seoul, Korea (the Republic of)
  • Han, Kyungdo, Soongsil University Department of Statistics and Actuarial Science, Dongjak-gu, Seoul, Korea (the Republic of)
  • Lee, Hyewon, AstraZeneca Korea Co Ltd, Seoul, Korea (the Republic of)
  • Nam, You-Seon, AstraZeneca Korea Co Ltd, Seoul, Korea (the Republic of)
  • Wittbrodt, Eric T., AstraZeneca, Gaithersburg, Maryland, United States
  • Fenici, Peter, AstraZeneca, Cambridge, United Kingdom
  • Kosiborod, Mikhail, Saint Luke's Mid America Heart Institute, Kansas City, Missouri, United States
  • L Heerspink, Hiddo Jan, University Medical Center Groningen, Groningen, Netherlands
  • Yoo, Soon-Jib, The Catholic University of Korea Bucheon Saint Mary's Hospital, Bucheon, Gyeonggi-do, Korea (the Republic of)
  • Kwon, Hyuk-Sang, The Catholic University of Korea Yeouido Saint Mary's Hospital, Yeongdeungpo-gu, Seoul, Korea (the Republic of)
Background

Real-world evidence from routine clinical practice elucidating the effects of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) on renal outcomes and mortality in patients with type 2 diabetes (T2D) is limited.

Methods

Using data from the Korean National Health Insurance Service database from January 2014 to December 2017, a total of 701,674 patients were identified with T2D. We divided these patients into new-users of SGLT-2i and new-users of other glucose-lowering drugs (oGLD). Using propensity scores, patients in the two groups were matched 1:1. We examined for the risk of end-stage renal disease (ESRD) and all-cause death.

Results

There were 45,016 patients in each group, and baseline characteristics were well-balanced between groups: mean age 58.1 ± 10.6 years; mean estimated glomerular filtration rate (eGFR) 89.2 ± 27.4 ml/min/1.73m2; 8% of patients had proteinuria. We identified 167 incident ESRD and 1,070 all-cause deaths during follow-up. Use of SGLT-2i versus oGLD was associated with a lower risk of ESRD (HR: 0.47; 95% confidence interval [CI]: 0.34 to 0.65) and all-cause death (HR: 0.82; 95% CI: 0.73 to 0.93). In a subgroup analysis by eGFR, initiation of SGLT2i vs oGLD was associated with lower risk of progression to ESRD among patients with eGFR 60-90 and <60 ml/min/1.73m2 and lower risk of all-cause death associated with SGLT-2i versus oGLD was observed across the entire range of renal function.

Conclusion

In this large nationwide study of Korean patients with T2D, initiation of SGLT-2i vs oGLD was associated with lower risk of ESRD and all-cause death.

Funding

  • Commercial Support –